Magnetic resonance spectroscopy (MRS) is a non-invasive technique that facilitates measurement of biochemical changes in the brain in vivo [
1]. It has been demonstrated to provide additional clinically relevant information in a wide variety of conditions, including brain tumors, metabolic conditions, and systemic diseases [
2]. The most common form of MRS is
1H-MRS or proton MRS. In contrast to other forms of magnetic resonance imaging (MRI) where protons in water molecules generate the overwhelming majority of the signal,
1H-MRS analyzes protons attached to molecules other than water. Only small, mobile, highly concentrated molecules (typically > 0.5 μmol/g tissue) can be measured, which in practice limits brain
1H-MRS to a restricted number of key metabolites. Useful metabolites including creatine,
N-acetylaspartate (NAA), myo-inositol, choline, glutamate, glutamine, and gamma-aminobutyric acid (GABA) can be assessed by examining the spectra generated using
1H-MRS. Individual metabolite concentrations can be assessed as either absolute concentrations or relative to other molecules (usually creatine) to produce a regionally specific molecular fingerprint. The main limitations of
1H-MRS in brain research relate to technicalities in generating robust spectra due to signal to noise ratio concerns. The crude resolution of centimeters compared to millimeters of conventional MRI also limits the precision of the technique in brain research. However, despite these limitations,
1H-MRS is becoming increasingly clinically relevant and is also contributing to our understanding of brain diseases such as Parkinson’s disease [
3], multiple sclerosis [
4], and epilepsy [
5]. Similarly,
1H-MRS is helping to uncover pathologies in neuropsychiatric illnesses such as schizophrenia [
6,
7], bipolar disorder [
8,
9], and anxiety [
10,
11].